The White House has dropped Dr. Heidi Overton's nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday, according to NBC News and CNN. The Senate health committee had been due to vote on her Wednesday. Axios was first to report the decision.
CBS News reported earlier Tuesday that Overton was struggling to win enough Republican votes on the Health, Education, Labor and Pensions Committee and that none of the committee's Democrats were expected to back her. NBC News said she would have needed 11 votes in the 21-member committee, so she could not afford to lose a single Republican if all Democrats opposed her. CBS News said the White House had already started talking to other possible candidates.
CBS News said her nomination ran into trouble over her testimony on the abortion drug mifepristone and her role in carrying out President Trump's pro-vaping policies on the Domestic Policy Council. Sen. Josh Hawley, a Missouri Republican, was among the skeptics, according to CBS News, after Overton sidestepped questions about a long-promised safety study of mifepristone.
Sens. Susan Collins of Maine and Lisa Murkowski of Alaska had not said how they would vote. NBC News reported that Murkowski criticized Overton at her hearing for not taking a clear position on the drug.
Committee Chairman Bill Cassidy, a Louisiana Republican, questioned whether she had enough managerial experience. He said before her September hearing that he had strong concerns and later said he was undecided. CNN reported that the nomination also exposed tensions between the Make America Healthy Again movement and more traditional conservative circles, and quoted a person familiar with the situation as saying she is “not MAHA.”
CBS News reported that Cassidy told it late Tuesday he saw a possible path for Overton to advance out of his committee. The committee had not told the White House it lacked the votes, and two sources said vote-counting efforts were still underway when the White House shared its decision Tuesday evening.
Kyle Diamantas is acting commissioner. The agency has had no Senate-confirmed leader since Dr. Marty Makary left in the spring, CBS News said. NBC News reported he resigned in May, in part over the administration's decision to authorize several fruit-flavored vaping products. CBS News cited sources who described friction over White House pressure on flavored vapes.
CBS News noted that the FDA oversees products that account for roughly 20% of consumer spending. NBC News said the agency is due to finish its safety review of mifepristone in March, one of the most consequential decisions it faces. The vacancy also extends a long stretch of upheaval at the top U.S. health agencies, NBC News reported.
Time is short. Democrats take control of the Senate in January, when Overton would have had to be renominated, and NBC News said her chances then would be slim. CBS News reported that the White House has spoken with candidates who could serve in an acting capacity and avoid Senate confirmation, and that two sources said Sen. Roger Marshall of Kansas, a doctor, is seeking the post. Marshall lost his reelection bid to Democrat Adam Hamilton earlier this month.
Cassidy said on CBS News' “Face the Nation” on Sunday that Republicans face a choice between a permanent commissioner who is not everyone's ideal pick and a series of short-term administrators with more influence from the health secretary.
Around Prague, based on reporting by CBS News, CNN, NBC News